AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...